Diagnosis and treatment of overactive bladder

Minerva Ginecologica

Volumn 57, Issue 5, 2005, Pages 501-520

  Miller, J J R ^a,b   Sand, P K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Evanston Continence Center   (United States)

Author keywords

Diseases, bladder; Overactive bladder; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; DARIFENACIN; DEETHYLOXYBUTININ; DICYCLOVERINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; DRUG METABOLITE; ESTROGEN; FLAVOXATE; HYOSCYAMINE; IMIPRAMINE; MEDROXYPROGESTERONE ACETATE; METFORMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; ORAL ANTIDIABETIC AGENT; OXYBUTYNIN; PLACEBO; PROGESTERONE; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

AGE; BEHAVIOR THERAPY; BLADDER INNERVATION; BLADDER SURGERY; CAUCASIAN; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CYSTOMETRY; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MECHANISM; DYSPEPSIA; ECHOGRAPHY; ELECTROMAGNETIC FIELD; ELECTROSTIMULATION THERAPY; EPIDEMIOLOGICAL DATA; ERYTHEMA; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEALTH CARE COST; HEART ARRHYTHMIA; HEART PALPITATION; HORMONE SUBSTITUTION; HUMAN; INSOMNIA; LACRIMATION; LIFESTYLE; MYDRIASIS; NAUSEA; NEUROMODULATION; NONHUMAN; OVERACTIVE BLADDER; PELVIS FLOOR; PREVALENCE; PRURITUS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; TACHYCARDIA; TRAINING; TREATMENT OUTCOME; URETHROCYSTOMETRY; VISUAL IMPAIRMENT; XEROSTOMIA;

FEMALE; HUMANS; RISK FACTORS; URINARY INCONTINENCE;

EID: 27844493205     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl 1988;114:5-19.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61: 37-49.
3. Moore KH, Richmond DH, Parys BT. Sex distribution of adult idiopathic detrusor instability in relation to childhood bedwetting. Br J Urol 1991;68:479-82.
4. Nitti VW. Clinical impact of overactive bladder. Rev Urol 2002;4:S2-S6.
5. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
6. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580-90.
7. Director's status report to council Senate's Special Committee on Aging Report. Bethesda, MD: National Institute on Aging: 1999.
8. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics 1996;9:11-23.
9. Roe B, May C. Incontinence and sexuality: findings from a qualitative perspective. J Adv Nurs 1999;30: 573-9.
10. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA 2004;291:986-95.
11. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5.
12. Wagner TH, Hu TW, Bentkover J, LeBlanc K, Stewart W, Corey R et al. Health-related consequences of over-active bladder. Am J Manag Care 2002;8 (19 Suppl): S598-607.
13. Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999;94:66-70.
14. Fonda D, Nickless R, Roth R. A prospective study of the incidence of urinary incontinence in an acute care teaching hospital and its implications on future service development. Aust Clin Rev 1988;8:102-7.
15. Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48: 721-5.
16. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-9.
17. Frewen WK. An objective assessment of the unstable bladder of psychosomatic origin. Br J Urol 1978;50: 246-9.
18. Beck RP, Arnusch D, King C. Results in treating 210 patients with detrusor overactivity incontinence of urine. Am J Obstet Gynecol 1976;125:593-6.
19. Bhatia NN, Bergman A. Cystometry: unstable bladder and urinary tract infection. Br J Urol 1986;58:134-7.
20. Khan Z, Bhola A, Starer P. Urinary incontinence during orgasm. Urology 1988;31:279-82.
21. Hilton P. Urinary incontinence during sexual intercourse: a common, but rarely volunteered, symptom. Br J Obstet Gynaecol 1988;95:377-81.
22. Wetle T, Scherr P, Branch LG, Resnick NM, Harris T, Evans D et al. Difficulty with holding urine among older persons in a geographically defined community: prevalence and correlates. J Am Geriatr Soc 1995;43: 349-55.
23. Jackson RA, Vittinghoff E, Kanaya AM, Miles TP, Resnick HE, Kritchevsky SB et al. Urinary incontinence in elderly women: findings from the Health, Aging, and Body Composition Study. Obstet Gynecol 2004;104:301-7.
24. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103: 254-60.
25. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21: 518-24.
26. Diokno AC, Brock BM, Herzog AR, Bromberg J. Medical correlates of urinary incontinence in the elderly. Urology 1990;36:129-38.
27. Brown JS, Seeley DG, Fong J, Black DM, Ensrud KE, Grady D. Urinary incontinence in older women: who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol 1996;87:715-21.
28. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
29. Brown JS, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y et al. for the Diabetes Prevention Program (DPP) Research Group. Incontinence in women with impaired glucose tolerance: results of the diabetes prevention program. J Urol 2004;171 (4 Suppl):325-6.
30. Griebling TL, Nygaard IE. The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in post-menopausal women. Endocrinol Metab Clin North Am 1997;26:347-60.
31. Ingelman-Sundberg A, Rosen J, Gustafsson SA, Carlstrom K. Cytosol estrogen receptors in the urogenital tissues in stress-incontinent women. Acta Obstet Gynecol Scand 1981;60:585-6.
32. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981;141:817-20.
33. Bergman A, Karram MM, Bhatia NN. Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest 1990;29:211-3.
34. Judge TG. The use of quinestradol in elderly incontinent women, a preliminary report. Gerontol Clin (Basel) 1969;11:159-64.
35. Van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburgh WH. The effect of estriol on the cytology of urethra and vagina in post-menopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol 1993;51:29-33.
36. Walter S. Detrusor hyperreflexia in female urinary incontinence treated pharmacologically. Urol Int 1978;33: 316-21.
37. Bump RC, Friedman CI. Intraluminal urethral pressure measurements in the female baboon: effects of hormonal manipulation. J Urol 1986;136:508-11.
38. Wilson PD, Faragher B, Butler B, Bu'Lock D, Robinson EL, Brown AD. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987;94:568-74.
39. Walter S, Kjaergaard B, Lose G, Andersen JT, Heisterberg L, Jacobsen H. Stress urinary incontinence in postmenopausal women treated with oral estrogen (estriol) and an alpha-adrenoceptor-stimulating agent (phenylpropanolamine): a randomized double-blind placebo-controlled study. Int Urogynecol J 1990;1: 74-9.
40. Samsioe G, Jansson I, Mellstrom D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas 1985;7:335-42.
41. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on postmenopausal urinary stress incontinence: a double-blind placebo-controlled trial. Br J Obstet Gynaecol 1999;106:711-8.
42. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol 1996;88: 745-9.
43. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snydert T. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-20.
44. Hilton P, Stanton SL. The use of intravaginal oestrogen cream in genuine stress incontinence. Br J Obstet Gynaecol 1983;90:940-4.
45. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-81.
46. Onuora C, Ardoin J, Dunnihoo D, Otterson W. Vaginal estrogen therapy in the treatment of urinary tract symptoms in postmenopausal women. Int Urogynecol J 1991;2:3-5.
47. Henalla S, Hutchins C, Robinson P, Macvicar J. Non-operative methods in the treatment of female genuine stress incontinence of urine. J Obstet Gynaecol 1989;9: 222-6.
48. Fonda D, Brimage PJ, D'Astoli M. Simple screening for urinary incontinence in the elderly: comparison of simple and multichannel cystometry. Urology 1993;42: 536-40.
49. Wiskind AK, Miller KF, Wall LL. One hundred unstable bladders. Obstet Gynecol 1994;83:108-12.
50. Sand PK, Ostergard DR. Urodynamics and the Evaluation of Female Incontinence: a practical guide. New York: Springer; 1997.
51. Van Venrooij GE, Boon TA. Extensive urodynamic investigation: interaction among diuresis, detrusor instability, urethral relaxation, incontinence and complaints in women with a history of urge incontinence. J Urol 1994;152:1535-8.
52. Porru D, Usai E. Standard and extramural ambulatory urodynamic investigation for the diagnosis of detrusor instability-correlated incontinence and micturition disorders. Neurourol Urodyn 1994;13:237-42.
53. Webb RJ, Ramsden PD, Neal DE. Ambulatory monitoring and electronic measurement of urinary leakage in the diagnosis of detrusor instability and incontinence. Br J Urol 1991;68:l48-52.
54. McInerney PD, Vanner TF, Harris SA, Stephenson TP. Ambulatory urodynamics. Br J Urol 1991;67:272-4.
55. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99.
56. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370-4.
57. Frewen W. Role of bladder training in the treatment of the unstable bladder in the female. Urol Clin North Am 1979;6:273-7.
58. Frewen WK. A reassessment of bladder training in detrusor dysfunction in the female. Br J Urol 1982;54: 372-3.
59. Burgio KL. Influence of behavior modification on overactive bladder. Urology 2002;60:72-6; discussion 77.
60. McCormick KA, Burgio KL. Incontinence: an update on nursing care measures. J Gerontol Nurs 1984;10:16-23.
61. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265: 609-13.
62. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11:560-5.
63. Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003;92:69-77.
64. Dallosso HM, Matthews RJ, McGrother CW, Donaldson MM, Shaw C. The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men. Public Health Nutr 2004;7:885-91.
65. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
66. Rovener ES, Wein AJ. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin. BJU Int 2000;86 Suppl 2:44-53; discussion 53-4.
67. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998;51:43-7.
68. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002;136: 641-3.
69. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002;22:133-45.
70. nd Annual Meeting of the International Continence Society, 2002, 28-30 August, Heidelberg, Germany.
71. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161:1809-12.
72. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999;54:420-3.
73. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000;95:718-21.
74. Chancellor MB, Appell RA, Sathyan G, Gupta SK. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001; 23:753-60.
75. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39:289-96.
76. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62: 237-42.
77. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998;349:285-92.
78. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
79. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10:283-9.
80. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D et al. Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63.
81. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21.
82. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003;92:741-7.
83. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
84. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-5, quiz 2435.
85. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003;4:436-40.
86. Hofner K, Oelke M, Machtens S, Grunewald V. Trospium chloride-an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336-43.
87. Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452-6.
88. Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492:243-50.
89. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93: 303-10.
90. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Ridder A. Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder. Neurourol Urodyn 2003;22:357-548 [Abstract 121].
91. Gulp DJ, Luo W, Richardson LA, Watson GE, Latchney LR. Both M1 and M3 receptors regulate exocrine secretion by mucous acini. Am J Physiol 1996;271: C1963-72.
92. Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol 2001;133:1035-40.
93. Mei L, Roeske WR, Izutsu KT, Yamamura HI. Characterization of muscarinic acetylcholine receptors in human labial salivary glands. Eur J Pharmacol 1990; 176:367-70.
94. Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F, Rump LC. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 2001;103:1638-43.
95. Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000;292:877-85.
96. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9; discussion 429.
97. rd Annual Meeting of the International Continence Society. 2003, October 5-9, Florence, Italy.
98. Wesnes K, Lipton R, Kolodner K, Edgar C. Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur Urol 2004;45:131.
99. Malone DC, Okano GJ. Treatment of urge incontinence in Veterans Affairs medical centers. Clin Ther 1999;21:867-77.
100. Soulard C, Pascaud X, Roman FJ, Grouhel A, Junien JL. Pharmacological evaluation of JO 1870: relation to the potential treatment of urinary bladder incontinence. J Pharmacol Exp Ther 1992;260:1152-8.
101. Peterson JS, Patton AJ, Noronha-Blob L. Mini-pig urinary bladder function: comparisons of in vitro anticholinergic responses and in vivo cystometry with drugs indicated for urinary incontinence. J Auton Pharmacol 1990;10:65-73.
102. Zeegers AGM, Kiesswetter H, Kramer AEJL. Conservative therapy of frequency, urgency and urge urinary incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. World J Urol 1989;5: 57-61.
103. Chappie CR, Parkhouse H, Gardener C, Milroy EJ. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 1990;66:491-4.
104. Meyhoff HH, Gerstenberg TC, NordlingJ. Placebo-the drug of choice in female motor urge incontinence? Br J Urol 1983;55:34-7.
105. Robinson JM, Brocklehurst JC. Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women. Br J Urol 1983;55:371-6.
106. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986;15:299-303.
107. Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. J Urol 1989;142: 1024-6.
108. Roupret M, Chartier-Kastler E, Aimeras C, Ayoub N, Haertig A, Richard F. Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter. J Urol 2004;172:236-9.
109. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071-5.
110. Katz IR, Sands LP, Bilker W, Difilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:80-13.